Recently, a poly(ADP-ribose) polymerase (PARP) inhibitor Olaparib was shown to trigger robust STING-dependent antitumor immune responses in breast cancer type 1 (BRCA1)-deficient ovarian cancer, which induces robust adaptive and innate antitumor immune responses. The gene discussed is STING1; the disease is ovarian cancer.